Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology.

ABSTRACT:

Introduction

The level of the presynaptic protein growth-associated protein 43 (GAP-43) in cerebrospinal fluid (CSF) has previously been shown to be increased in Alzheimer's disease (AD) and thus may serve as an outcome measure in clinical trials and facilitate earlier disease detection.

Methods

We developed an enzyme-linked immunosorbent assay for CSF GAP-43 and measured healthy controls (n = 43), patients with AD (n = 275), or patients with other neurodegenerative diseases (n = 344). In a subpopulation (n = 93), CSF GAP-43 concentrations from neuropathologically confirmed cases were related to Aβ plaques, tau, α-synuclein, and TDP-43 pathologies.

Results

GAP-43 was significantly increased in AD compared to controls and most neurodegenerative diseases and correlated

SUBMITTER: Sandelius A 

PROVIDER: S-EPMC6333489 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature